Filana Therapeutics (FLNA) Depreciation & Amortization (CF) (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Depreciation & Amortization (CF) of $300000.0 for Q2 2026, up 50.0% year-over-year from $200000.0 in Q2 2025, and up 23.46% quarter-over-quarter from $243000.0 in Q1 2026.
Filana Therapeutics (FLNA) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Filana Therapeutics' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $300000.0 for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 50.0% year-over-year to $300000.0; the TTM figure through Jun 2026 stood at $1.0 million (up 55.65% YoY), while the FY2025 annual figure was $903000.0, down 5.15% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $300000.0, up from $243000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $311000.0 in Q1 2024, with the low at $52000.0 in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $255000.0 (2023), against an average of $234277.8.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 17700.0% in 2022, then sank 80.52% in 2024.
- Filana Therapeutics' Depreciation & Amortization (CF) stood at $271000.0 in 2022, then slipped by 1.48% to $267000.0 in 2023, then tumbled by 80.52% to $52000.0 in 2024, then surged by 482.69% to $303000.0 in 2025, then fell by 0.99% to $300000.0 in 2026.
- Business Quant data shows FLNA's Depreciation & Amortization (CF) at $300000.0 in Q2 2026, $243000.0 in Q1 2026, and $303000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 243,000.00 |
| Mar 31, 2026 | 243,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 311,000.00 |
| Mar 31, 2024 | 311,000.00 |